Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment.
Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and the Cooperative Meeting with Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)
Immunopathogenesis of neuromyelitis optica.
Long-Term Effects of Exposure to Disease-Modifying Drugs in the Offspring of Mothers with Multiple Sclerosis: A Retrospective Chart Review.
MS Research Roundup: January 29, 2014
Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations.
Episode 56 with Dr. Gavin Giovannoni, on early phase 3 results of ocrelizumab, the first experimental drug to show some benefit in a progressive form of multiple sclerosis in a major trial
Regulatory CD4(+) T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis.
MHC transmission: insights into gender bias in MS susceptibility.
Blood Brain Barrier Meeting
Summit 2013 + Expo
Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-Related Hospitalizations: Integrated Analysis of the Delayed-Release Dimethyl Fumarate Phase III Studies.
The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis.
Gender and the hygiene hypothesis.
Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis.
Neurodegeneration: From Multiple Sclerosis to Alzheimer’s Disease
Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis.
HLA-DRB1*15:01 and multiple sclerosis: a female association?
MS Research Roundup: January 31, 2014
Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System.
Synthetic Biologics Reports UCLA Announcement of Preliminary Positive Topline Efficacy and Safety Results from Investigator-Led Phase II Study of Trimesta™ for RRMS
Biogen Idec reports positive top-line results from Phase 2 anti-LINGO-1 trial in people with acute optic neuritis
Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis.
Gender differences in 1,25 dihydroxyvitamin D3 immunomodulatory effects in multiple sclerosis patients and healthy subjects.
Sex ratio of multiple sclerosis and clinical phenotype.

Pages